Metformin may reduce oral cancer risk in patients with type 2 diabetes

Oncotarget

Volumn 7, Issue 2, 2016, Pages 2000-2008

  Tseng, Chin Hsiao ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

Diabetes mellitus; Metformin; Oral cancer; Taiwan

Indexed keywords

ANTIDIABETIC AGENT; INSULIN; METFORMIN;

ADD ON THERAPY; ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CONTROLLED STUDY; DRUG EFFECT; DRUG EXPOSURE; DRUG USE; FEMALE; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MALE; MOUTH CANCER; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; RISK REDUCTION; TAIWAN; TREATMENT DURATION; CASE CONTROL STUDY; COMPARATIVE STUDY; COMPLICATION; DIABETES MELLITUS, TYPE 2; FOLLOW UP; MIDDLE AGED; MOUTH NEOPLASMS; PROGNOSIS; RISK FACTOR;

ADULT; AGED; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; MOUTH NEOPLASMS; PROGNOSIS; RISK FACTORS;

EID: 84957665963     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6626     Document Type: Article

References (50)

1. Fan C, Wang Y, Liu Z, Sun Y, Wang X, Wei G, Wei J. Metformin exerts anticancer effects through the inhibition of the Sonic hedgehog signaling pathway in breast cancer. Int J Mol Med. 2015;36:204-14.
2. Moon HS, Mantzoros CS. Regulation of cell proliferation and malignant potential by irisin in endometrial, colon, thyroid and esophageal cancer cell lines. Metabolism. 2014;63:188-93.
3. Gou S, Cui P, Li X, Shi P, Liu T, Wang C. Low concentrations of metformin selectively inhibit CD133+ cell proliferation in pancreatic cancer and have anticancer action. PLoS One. 2013;8:e63969.
4. Karnevi E, Said K, Andersson R, Rosendahl AH. Metformin-mediated growth inhibition involves suppression of the IGF-I receptor signalling pathway in human pancreatic cancer cells. BMC Cancer. 2013;13:235.
5. Kato K, Gong J, Iwama H, Kitanaka A, Tani J, Miyoshi H, Nomura K, Mimura S, Kobayashi M, Aritomo Y, Kobara H, Mori H, Himoto T, et al. The antidiabetic drug metformin inhibits gastric cancer cell proliferation in vitro and in vivo. Mol Cancer Ther. 2012;11:549-60.
6. Kato H, Sekine Y, Furuya Y, Miyazawa Y, Koike H, Suzuki K. Metformin inhibits the proliferation of human prostate cancer PC-3 cells via the downregulation of insulin-like growth factor 1 receptor. Biochem Biophys Res Commun. 2015;461:115-21.
7. Tseng CH. Diabetes, metformin use, and colon cancer: A population-based cohort study in Taiwan. Eur J Endocrinol. 2012;167:409-16.
8. Tseng CH. Metformin may reduce bladder cancer risk in Taiwanese patients with type 2 diabetes. Acta Diabetol. 2014;51:295-303.
9. Tseng CH. Metformin may reduce breast cancer risk in Taiwanese women with type 2 diabetes. Breast Cancer Res Treat. 2014;145:785-90.
10. Tseng CH. Metformin significantly reduces incident prostate cancer risk in Taiwanese men with type 2 diabetes mellitus. Eur J Cancer. 2014;50:2831-7.
11. Tseng CH. Metformin reduces thyroid cancer risk in Taiwanese patients with type 2 diabetes. PLoS One. 2014;9:e109852.
12. Tseng CH. Metformin and endometrial cancer risk in Chinese women with type 2 diabetes mellitus in Taiwan. Gynecol Oncol. 2015;138:147-53.
13. Tseng CH. Metformin reduces ovarian cancer risk in Taiwanese women with type 2 diabetes mellitus. Diabetes Metab Res Rev. 2015;31:619-26.
14. Sikka A, Kaur M, Agarwal C, Deep G, Agarwal R. Metformin suppresses growth of human head and neck squamous cell carcinoma via global inhibition of protein translation. Cell Cycle. 2012;11:1374-82.
15. Rêgo DF, Pavan LM, Elias ST, De Luca Canto G, Guerra EN. Effects of metformin on head and neck cancer: a systematic review. Oral Oncol. 2015;51:416-22.
16. Sandulache VC, Hamblin JS, Skinner HD, Kubik MW, Myers JN, Zevallos JP. Association between metformin use and improved survival in patients with laryngeal squamous cell carcinoma. Head Neck. 2014;36:1039-43.
17. Skinner HD, Sandulache VC, Ow TJ, Meyn RE, Yordy JS, Beadle BM, Fitzgerald AL, Giri U, Ang KK, Myers JN. TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence. Clin Cancer Res. 2012;18:290-300.
18. Yen YC, Lin C, Lin SW, Lin YS, Weng SF. Effect of metformin on the incidence of head and neck cancer in diabetics. Head Neck. 2015;37:1268-73.
19. Yang XL, Ma RC, So WY, Kong AP, Xu G, Chan JC. Addressing different biases in analysing drug use on cancer risk in diabetes in non-clinical trial settings-what, why and how? Diabetes Obes Metab. 2012;14:579-85.
20. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158:915-20.
21. Suissa S. Immortal time bias in pharmaco-epidemiology. Am J Epidemiol. 2008;167:492-9.
22. Austin PC. The performance of different propensity score methods for estimating marginal hazard ratios. Stat Med. 2013;32:2837-49.
23. Tseng CH. Oral cancer in Taiwan: is diabetes a risk factor? Clin Oral Investig. 2013;17:1357-64.
24. Kourelis TV, Siegel RD. Metformin and cancer: new applications for an old drug. Med Oncol. 2012;29:1314-27.
25. Petti S, Masood M, Scully C. The magnitude of tobacco smoking-betel quid chewing-alcohol drinking interaction effect on oral cancer in South-East Asia. A meta-analysis of observational studies. PLoS One. 2013;8:e78999.
26. Gupta B, Johnson NW. Systematic review and metaanalysis of association of smokeless tobacco and of betel quid without tobacco with incidence of oral cancer in South Asia and the Pacific. PLoS One. 2014;9:e113385.
27. Tseng CH. Betel nut chewing is associated with hypertension in Taiwanese type 2 diabetic patients. Hypertens Res. 2008;31:417-23.
28. Tseng CH. Betel nut chewing and subclinical ischemic heart disease in diabetic patients. Cardiol Res Pract. 2011;451489.
29. van Stralen KJ, Dekker FW, Zoccali C, Jager KJ. Confounding. Nephron Clin Pract. 2010;116:c143-7.
30. Mravak-Stipetic M, Sabol I, Kranjcic J, Kneževic M, Grce M. Human papillomavirus in the lesions of the oral mucosa according to topography. PLoS One. 2013;8:e69736.
31. Zavras AI, Shanmugam P, Shetty D, Dolecek TA, Kaste LM. Oral and pharyngeal cancer in women. Dent Clin North Am. 2013;57:339-55.
32. Dai YN, Wang JH, Zhu JZ, Lin JQ, Yu CH, Li YM. Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers therapy and colorectal cancer: a systematic review and meta-analysis. Cancer Causes Control. 2015;26:1245-55.
33. Bonovas S. Statins: do they have a potential role in cancer prevention and modifying cancer-related outcomes? Drugs. 2014;74:1841-8.
34. Crusz SM, Balkwill FR. Inflammation and cancer: advances and new agents. Nat Rev Clin Oncol. 2015;12:584-96.
35. Sahingur SE, Yeudall WA. Chemokine function in periodontal disease and oral cavity cancer. Front Immunol. 2015;6:214.
36. Mohamed HG, Idris SB, Mustafa M, Ahmed MF, Åstrøm AN, Mustafa K, Ibrahim SO. Impact of chronic periodontitis on levels of glucoregulatory biomarkers in gingival crevicular fluid of adults with and without type 2 diabetes. PLoS One. 2015;10:e0127660.
37. Artese HP, Foz AM, Rabelo Mde S, Gomes GH, Orlandi M, Suvan J, D'Aiuto F, Romito GA. Periodontal therapy and systemic inflammation in type 2 diabetes mellitus: a metaanalysis. PLoS One. 2015;10:e0128344.
38. Chu NJ, Armstrong TD, Jaffee EM. Nonviral oncogenic antigens and the inflammatory signals driving early cancer development as targets for cancer immunoprevention. Clin Cancer Res. 2015;21:1549-57.
39. Saisho Y. Metformin and inflammation: Its potential beyond glucose-lowering effect. Endocr Metab Immune Disord Drug Targets. 2015;15:196-205.
40. Eikawa S, Nishida M, Mizukami S, Yamazaki C, Nakayama E, Udono H. Immune-mediated antitumor effect by type 2 diabetes drug, metformin. Proc Natl Acad Sci U S A. 2015;112:1809-14.
41. Corominas-Faja B, Quirantes-Piné R, Oliveras-Ferraros C, Vazquez-Martin A, Cufí S, Martin-Castillo B, Micol V, Joven J, Segura-Carretero A, Menendez JA. Metabolomic fingerprint reveals that metformin impairs one-carbon metabolism in a manner similar to the antifolate class of chemotherapy drugs. Aging (Albany NY). 2012;4:480-98.
42. Xun YH, Zhang YJ, Pan QC, Mao RC, Qin YL, Liu HY, Zhang YM, Yu YS, Tang ZH, Lu MJ, Zang GQ, Zhang JM. Metformin inhibits hepatitis B virus protein production and replication in human hepatoma cells. J Viral Hepat. 2014;21:597-603.
43. del Campo JA, García-Valdecasas M, Rojas L, Rojas á, Romero-Gómez M. The hepatitis C virus modulates insulin signaling pathway in vitro promoting insulin resistance. PLoS One. 2012;7:e47904.
44. Kao SY, Lim E. An overview of detection and screening of oral cancer in Taiwan. Chin J Dent Res. 2015;18:7-12.
45. Tseng CH. Pioglitazone and oral cancer risk in patients with type 2 diabetes. Oral Oncol. 2014;50:98-103.
46. Tseng CH. Diabetes but not insulin increases the risk of lung cancer: a Taiwanese population-based study. PLoS One. 2014;9:e101553.
47. Tseng CH. Pioglitazone and bladder cancer: a populationbased study of Taiwanese. Diabetes Care. 2012;35:278-80.
48. Chang L. A study of validation on comorbidity derived from claims data [Master thesis]: National Yang-Ming University; 2004. http://etd.lib.nctu.edu.tw/cgi-bin/gs32/ymgsweb.cgi/ccd=ji3XTg/search#result (Accessed: October 26, 2015).
49. Parsons LS. Performing a 1:N case-control match on propensity score. http://www.google.com.tw/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&ved=0CBsQFjAAahUKEwibi7HllcnIAhUDoJQKHVeZA9A&url=http%3A%2F%2Fwww2.sas.com%2Fproceedings%2Fsugi29%2F165-29.pdf&usg=AFQjCNFOHGWYu8E8Bn4-Bo1TUiJKtT987Q (last accessed October 17, 2015).
50. Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med. 2015;34:3661-79.